Log SIV RNA copies ml -1 Log SIV RNA copies ml -1 Day 10 Day 14 Assay sensitivity is 50 RNA copies ml 21 . Red arrows indicate initiation of ART. Black dots below x-axis indicate sampling time points. 24 -week course of suppressive therapy with no detectable viral blips ( Fig. 1a ), demonstrating the potency and consistency of this ART regimen. Moreover, ultrasensitive plasma viral load assays at week 20 also proved negative (#6 RNA copies ml 21 ) 13 in all animals (Extended Data Fig. 2 ). In addition, viral sequences from stimulated peripheral blood mononuclear cells (PBMCs) from ART-suppressed, SIV-infected monkeys using the same ART regimen revealed no viral sequence evolution over 6 months in a separate study (J.B.W., unpublished observations). Furthermore, treatment intensification studies in other SIV-infected rhesus monkeys in which the protease inhibitor darunavir was added to the current ART regimen did not lead to enhanced virological control (R.G., unpublished observations). Taken together, these data indicate that the ART regimen that was used in the present study was fully suppressive. We next assessed the development of SIV-specific humoral and cellular immune responses in these animals. Monkeys treated on day 3 after infection developed no detectable SIV Env-specific antibody responses by enzyme-linked immunosorbent assay (ELISA) ( Fig. 2a ) and no detectable SIV Env-, Pol-or Gag-specific T lymphocyte responses by interferon (IFN)-c ELISPOT assays (Fig. 2b ) at weeks 4, 10, and 20 or 24 of infection. In contrast, monkeys treated on days 7, 10 and 14 developed detectable but lower SIV-specific humoral and cellular immune responses as compared with untreated controls, presumably as a result of reduced antigenic stimulus after ART initiation. Multiparameter intracellular cytokine staining (ICS) assays confirmed that SIV Gag-specific CD8 1 and CD4 1 T lymphocyte responses were undetectable in animals treated on day 3 and were lower in animals treated on days 7, 10 and 14 as compared with untreated controls (Extended Data Figs 3 and 4). Gag-specific CD8 1 and CD4 1 T lymphocytes in monkeys treated on days 7, 10 and 14 also exhibited reduced immune activation and proliferation as measured by Ki67 expression (Extended Data Fig. 4 ). These data demonstrate that initiation of ART on day 3 blocked the emergence of plasma viraemia and abrogated the induction of SIV-specific humoral and cellular immune responses.
We next determined the impact of early ART on levels of proviral DNA 14 in PBMCs, lymph node mononuclear cells (LNMCs) and gastrointestinal mucosa mononuclear cells (GMMCs) over the course of 24 weeks of treatment with suppressive ART. In monkeys that initiated ART on day 3, there was a striking anatomical discordance with no proviral DNA detected in PBMCs at any time point (,3 DNA copies per 10 6 cells) ( Fig. 3a) . In contrast, clear but low levels of proviral DNA were detected in inguinal LNMCs and in colorectal GMMCs in these animals, although proviral DNA declined to undetectable or nearly undetectable levels in three of four of these animals by week 24. In monkeys treated with ART on days 7, 10 and 14, proviral DNA was readily detected in PBMCs as well as in LNMCs and GMMCs ( Fig. 3b-d ). Moreover, in animals treated with ART on days 10 and 14, proviral DNA in LNMCs appeared to stabilize by week 12 with minimal subsequent decline, consistent with a stable viral reservoir ( Fig. 3c, d ). In untreated animals, proviral DNA was markedly higher than in ART-treated animals with minimal decline over time ( Fig. 3e ). Analysis of sorted cell subpopulations demonstrated that proviral DNA was found primarily in central memory and transitional memory CD4 1 T lymphocytes in lymph nodes on day 3 and in both PBMCs and lymph nodes on day 7 after SIV infection (Extended Data Fig. 5 ). 
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These data indicate that initiation of ART on day 3 reduced levels of proviral DNA at week 24 by at least 2.2 log in PBMCs (P , 0.0001; Fig. 3f ), 1.0 log in LNMCs (P 5 0.004; Fig. 3g ), and 0.9 log in GMMCs (P 5 not significant; Fig. 3h ) as compared with initiation of ART on day 14. The high variability in the GMMC samples probably reflected sampling variation in this anatomical compartment. Compared to untreated animals, initiation of ART on day 3 reduced levels of proviral DNA at week 24 by at least 3.3 log in PBMCs (P , 0.0001; Fig. 3f ) and 3.1 log in LNMCs (P , 0.0001; Fig. 3g ).
At week 24, ART was discontinued, and monkeys were monitored twice weekly for evidence of viral rebound. Viral rebound, defined as plasma viral RNA .50 copies ml 21 , occurred in all animals (Fig. 4a ). In particular, viral rebound occurred in four of four animals that initiated ART on day 3, albeit with threefold delayed kinetics as compared with animals that initiated ART at later time points (median 21 days to viral rebound in the day 3 treated animals compared with 7 days in the day 14 treated animals; P , 0.001; Fig. 4b ). The median log setpoint viral load after rebound, defined as viral loads on days 56-112 following ART discontinuation, was also 1.04 log RNA copies ml 21 lower for all the ART-treated animals as compared with untreated controls (4.59 log RNA copies ml 21 for all treatment groups combined versus 5.63 log RNA copies ml 21 for untreated monkeys; P 5 0.01; Fig. 4c ), suggesting that there is a benefit to early ART, although no significant differences were observed among setpoint viral loads in the day 3, 7, 10 and 14 treatment groups. Setpoint viral loads in the untreated animals were comparable with historical controls 9, 10 . Taken together, these data show that the persistent viral reservoir was seeded by day 3 of infection and led to viral rebound in all monkeys after ART discontinuation.
To gain mechanistic insight into the kinetics of the viral rebound, we used viral dynamics modelling 15, 16 (see Methods; Extended Data Fig. 6 and Extended Data Table 2 ). Initiation of ART on day 3 as compared with days 7, 10 and 14 resulted in lower modelled residual viral loads at the time of ART discontinuation (P 5 0.01) and a trend towards a greater viral growth rate R 0 during viral rebound (P 5 0.06), but no difference in post-rebound setpoint viral loads (Extended Data Fig. 7 ). Average R 0 during viral rebound was 4.2 6 1.8 in the day 3 treated animals as compared with 2.3 6 0.6 in the day 14 treated animals (P 5 0.05; Extended Data Fig. 7) , presumably reflecting the partially effective SIV-specific immune responses in the latter group (Fig. 2 ). Total plasma viraemia during acute infection was interpolated and calculated as the area under the curve for pre-ART viral loads (AUC VL) (Extended Data Fig. 8 ). Consistent with recent findings in acute HIV-1 infection in humans 16 , the AUC VL during acute infection correlated with levels of proviral DNA in PBMCs (P , 0.0001; Fig. 5a ), LNMCs (P 5 0.005; Fig. 5b ) and GMMCs (P 5 0.04; data not shown) at the time of ART discontinuation. Moreover, both the AUC VL (P , 0.0001; Fig. 5c ) and proviral DNA in PBMCs at the time of ART discontinuation (P 5 0.003; Fig. 5d ) correlated inversely with the interpolated time to viral rebound. These data suggest that total plasma viraemia during acute infection and proviral DNA immediately before ART discontinuation may predict the time to viral recrudescence.
We show that the viral reservoir can be seeded substantially earlier than previously recognized. After intrarectal SIV infection of rhesus monkeys, the viral reservoir was seeded during the first few days of infection, during the eclipse phase, and before detectable viraemia, probably in the mucosal and lymphoid tissues that represent the first sites of viral replication 17 . Consistent with this finding, we observed proviral DNA in lymph nodes and in gastrointestinal mucosa but not in PBMCs in monkeys treated on day 3 after infection ( Fig. 3a and Extended Data Fig. 5 ). The observation that the viral reservoir can be seeded before detectable viraemia suggests that substantial pathogenesis occurs in tissues in the first few days after mucosal virus exposure and prior to virus replication in peripheral blood, which has important implications for HIV-1 therapeutic and eradication strategies.
Our data are concordant with recent clinical studies that have demonstrated that early ART can reduce the size of the viral reservoir and delay or reduce viral rebound after ART discontinuation in humans [18] [19] [20] [21] [22] . Our findings similarly show that early ART decreased proviral DNA in blood and tissues ( Fig. 3f-h ) and delayed and reduced viral rebound (Fig. 4b, c ) after ART discontinuation in SIV-infected rhesus monkeys. Moreover, 
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our observations extend previous studies that have shown effective postexposure prophylaxis with short courses of ART when initiated 24 h after SIV infection in monkeys 23, 24 . However, in the present study, initiation of suppressive ART even as early as day 3 after infection failed to eliminate the viral reservoir and did not prevent viral rebound despite 24 weeks of fully suppressive ART. In addition, our data ( Fig. 4a) are consistent with clinical studies that have shown that the vast majority of HIV-1-infected individuals who initiate ART during acute infection show viral rebound after discontinuation of ART [25] [26] [27] .
Our findings contrast with the sustained remission and potential cure of a viraemic baby that was treated with ART at 30 h of life 28 . It is possible that this baby was inoculated parenterally with maternal cells instead of mucosally with virus, resulting in rapid viraemia without a previraemic eclipse phase of viral replication in mucosal and lymphoid tissues. The positive outcome in this baby therefore might have reflected the route of transmission, the lack of an eclipse phase, the very rapid initiation of ART, and/or the paucity of memory CD4 1 T lymphocytes in the neonatal immune system 29 .
Clinical studies are required to confirm our observations, since important differences exist between SIV infection of rhesus monkeys and HIV-1 infection of humans. For example, the SIV dose used in the present study in monkeys was selected to limit the number of transmitted/founder viruses but also to infect all animals 8 and thus was substantially higher than typical HIV-1 doses in humans. Nevertheless, the higher challenge dose has been shown to shorten the eclipse period and to lead to earlier plasma viraemia 8 . Additional differences may also exist between SIVinfected rhesus monkeys and HIV-1-infected humans.
The strikingly early seeding of the viral reservoir within the first few days of infection is sobering and presents new challenges to HIV-1 eradication strategies. If HIV-1 similarly seeds a persistent viral reservoir in mucosal and lymphoid tissues during the eclipse phase of infection and before viraemia after sexual exposure in humans, then it will be very difficult to initiate ART before reservoir seeding, since viraemia is typically used for the clinical diagnosis of acute HIV-1 infection. Taken together, our data suggest that extremely early initiation of ART, extended ART duration, and probably additional interventions that target the viral reservoir will be required for HIV-1 eradication. Moreover, an improved understanding of the virological parameters that predict viral rebound after ART discontinuation will help guide future HIV-1 eradication efforts. Note added in proof: Since the acceptance of this paper, the 'Mississippi baby' that was treated with ART at 30 h of life and had a prolonged remission off therapy has now developed detectable levels of HIV-1 replication and has restarted therapy, demonstrating that early ART did not eradicate the viral reservoir in this child.
METHODS
Animals. Twenty outbred, Indian-origin, young adult, male and female rhesus monkeys (M. mulatta) were genotyped and selected as negative for the protective MHC class I alleles Mamu-A*01, Mamu-B*08 and Mamu-B*17. Animals expressing susceptible and resistant Trim5a alleles were distributed amongst the groups. Animals were otherwise randomly allocated to groups. All monkeys were housed at Bioqual, Rockville, Maryland. Animals were infected with 500 TCID 50 of our SIV MAC251 challenge stock [8] [9] [10] by the intrarectal route. Monkeys were bled up to two times per week for viral load determinations. Assays were performed blinded. All animal studies were approved by the appropriate Institutional Animal Care and Use Committee (IACUC). ART regimen. The pre-formulated antiretroviral therapy (ART) cocktail contained two reverse transcriptase inhibitors, 20 mg ml 21 tenofovir (TFV) and 50 mg ml 21 emtricitabine (FTC) plus 2.5 mg ml 21 of the integrase inhibitor dolutegravir (DTG) in a solvent containing 25% (v/v) polyethylene glycol 400 (PEG-400), 15% (w/v) captisol and 0.075 N sodium hydroxide (NaOH) in water. This ART cocktail was administered once daily at 1 ml kg 21 body weight via the subcutaneous route. The cocktail was prepared by mixing DTG stock solution (10 mg ml 21 of DTG in PEG-400), TFV and FTC stock solution (80 mg ml 21 of TFV and 200 mg ml 21 of FTC in 0.3 N NaOH), and 30% (w/w) captisol solution at a 1:1:2 (v:v:v) ratio. The final solution was clear and at pH ,6. It was sterile filtered, aliquoted into sterile glass vials in a biosafety cabinet, and frozen at 220 uC until used. Cellular immune assays. SIV-specific cellular immune responses were assessed by IFN-c ELISPOT assays and multiparameter ICS assays essentially as previously described 9 . Twelve-colour ICS assays were performed with the Aqua green-fluorescent reactive dye (Invitrogen, L23101) and predetermined titres of monoclonal antibodies (Becton Dickinson) against CD3 (SP34; Alexa Fluor 700), CD4 (OKT4; BV711, Biolegend), CD8 (SK1; allophycocyanin-cyanine 7 (APC-Cy7)), CD28 (L293; BV610), CD95 (DX2; allophycocyanin (APC)), CD69 (TP1.55.3; phycoerythrin-Texas red (energy-coupled dye; ECD); Beckman Coulter), IFN-c (B27; phycoerythrin-cyanine 7 (PE-Cy7)), Ki67 (B56; fluorescein isothiocyanate (FITC)), CCR5 (3A9; phycoerythrin (PE)), CCR7 (3D12; Pacific Blue) and PD-1(EH21.1; peridinin chlorophyll-A-cyanine 5.5 (PerCP-Cy5.5)). IFN-c backgrounds were consistently ,0.01% in PBMCs. Humoral immune assays. SIV Env-specific antibody responses were assessed by a direct ELISA essentially as previously described 9 . Viral RNA assays. Viral RNA was isolated from cell-free plasma using a viral RNA extraction kit (Qiagen) and was quantitated essentially as previously described 11 . RNA was isolated by phenol-chloroform purification followed by ethanol precipitation. All purified RNA preparations were quantified by optical density. Quantitative RT-PCR was conducted in a two-step process. First, RNA was reverse transcribed in parallel with an SIV-gag RNA standard using the gene-specific primer sGag-R 59-CACTAGGTGTCTCTGCACTATCTGTTTTG-39. All samples were then treated with RNase H (Stratagene) for 20 min at 37 uC. Primer sequences were adapted from those described 11 including the forward primer sGag-F: 59-P: 59-CTTCCTCAGTG TGTTTCACTTTCTCTTCTGCG-39, linked to Fam and BHQ (Invitrogen). All reactions were carried out on a 7300 ABI Real-Time PCR system (Applied Biosystems) in triplicate according to the manufacturer's protocols. Ultrasensitive viral load assays were performed essentially as described 13 . Proviral DNA assays. Lymph node and gastrointestinal mucosal biopsies were processed as single-cell suspensions, and levels of tissue-specific proviral DNA were quantitated as previously described 14 . Total cellular DNA was isolated from 5 3 10 6 cells using a QIAamp DNA Blood Mini kit (Qiagen). The absolute quantification of viral DNA in each sample was determined by qPCR using primers specific to a conserved region of SIV MAC239 . All samples were directly compared to a linear virus standard and the simultaneous amplification of a fragment of the human GAPDH gene. The sensitivity of linear standards was compared against the 3D8 cell line as a reference standard as described 14 . PCR assays were performed with 100-200 ng sample DNA. Viral dynamics modelling. Plasma viral loads pre-treatment, during treatment, and after treatment interruption were fit to a viral dynamics model to determine key parameters 12 . In order to derive individual level estimates with limited data points for each animal, we used a simplified version of the full system of differential equations describing the viral dynamics model, which had fewer parameters and could be solved analytically. All fits were evaluated using the nlinfit function in the MATLAB Statistical Toolbox. For acute infection in all animals treated on days 7, 10 or 14, and for rebound in all animals, data points below the limit of detection were treated as missing data (except for the last undetectable value after infection or interruption, which we took to equal the detection limit of 50 copies ml 21 ). Treating undetectable viral load values as left-censored data using a maximum likelihood approach did not noticeably change the results.
Pre-treatment and during treatment: We fit the viral dynamics observed following infection and treatment up to week 24 using a three-parameter piecewise function:
where t ART , the time that treatment was started, was defined based on the cohort as 3, 7, 10 or 14 days. Here v 0 is the effective infectious viral load from which the infection starts, a is the growth rate of viral load during acute infection, and d is the decay rate of viral load once treatment is started (if treatment is effective, the lifespan of infected cells is approximately 1/d). In essence, the model allows viral load to increase exponentially until treatment begins, and then decrease exponentially until it is below the detection limit. This approximates the observed dynamics well because a stable setpoint was not reached before treatment, and insufficient data points above the detection limit existed during viral decay to observe biphasic behaviour.
The basic reproductive ratio of the infection, defined as the average number of new infected cells produced by a single infected cell during early infection, can be calculated from these parameters as R 0 5 a/d 1 1. However, others have reported 12 that due to the intracellular delay between infection and the production of virus, this formula underestimates R 0 . To correct for this effect, we used a modified expression, R 0 5 (a/d 1 1)(a p 1 1), where p is the average length of the exponentially distributed delay time (which we take to be 1 day).
The AUC VL was used as an estimate of the total number of cells infected prior to treatment 15, 16 , which is a reasonable approximation for acute SIV infection since CD4 1 T-cell levels do not change consistently or significantly. We assumed that ART was fully effective so that there were no new infections after ART initiation, leading to the following formula: No fits were conducted for animals treated after 3 days, since all observed viral load values were below the limit of detection. To estimate the AUC VL for these, we used the average values of v 0 and a from the remaining 12 animals in the above formula with t ART 5 3.
Post-ART discontinuation: We fit the viral dynamics observed after ART discontinuation (starting at week 24) using a separate three-parameter function:
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Here t is the time since interruption. The parameter v r is the infectious residual viral load from which the infection starts, r is the growth rate of viral load during rebound, and v max is the viral setpoint reached after rebound. This logistic equation is an approximation to the full viral dynamics model that smooths out both high frequency fluctuations in viral load and lags in uninfected CD4 1 T-cell dynamics (such as overshooting the setpoint) 15 . Using these fits, we can interpolate the time at which viral load crossed the threshold of 50 copies ml 21 to define the rebound time. Similar to pre-treatment, we can calculate the post-rebound basic reproductive ratio as R 0 5 (r/d 1 1)(r p 1 1), where d is the viral decay rate measured during treatment and p is the intracellular delay between infection and virion production (which we take to be 1 day). Statistical analyses. All comparisons between cohorts were done using unpaired, equal variance, one-tailed t-tests. Correlation analysis was carried out in using the MATLAB corrcoef function (Pearson correlation). The standardized major axis method was employed for regression analysis (also known as 'geometric mean regression' or 'reduced major axis regression') using the gmregress function for the MATLAB Statistical Toolbox (available at http://www.mathworks.com/matlabcen
